After COVID-19: Lung Cancer Screening and Treatment - Episode 2

Opportunities and Challenges With Lung Cancer Screening Following COVID-19

James L. Mulshine, MD, professor of internal medicine, as well as associate director of the Institute of Translation Medicine at Rush University, shared some of the challenges that have stemmed from the COVID-19 pandemic and how it has impacted lung cancer screening in the United States.

EP. 1: Introducing the Post-Pandemic Change With Lung Cancer Screening
Now Viewing
EP. 2: Opportunities and Challenges With Lung Cancer Screening Following COVID-19
EP. 3: How to Reduce Lung Cancer Screening Disparities After COVID-19
EP. 4: The Effects of COVID-19 and Vaccinations in Non–Small Cell Lung Cancer
EP. 5: Therapeutic Approaches in Small Cell Lung Cancer
EP. 6: 2021 USPSTF Lung Cancer Screening Recommendations
EP. 7: Concluding Remarks in Lung Cancer Screening Following COVID-19

James L. Mulshine, MD, professor of internal medicine, as well as associate director of the Institute of Translation Medicine at Rush University, shared some of the challenges that have stemmed from the COVID-19 pandemic and how it has impacted lung cancer screening in the United States.

In this segment, Mulshine also highlights how the public health crisis led to opportunities for improvement in the lung cancer landscape.